PLX Stock Analysis: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.06
-0.03 (-1.44%)
▼
5d:
+5.1%
30d:
+3.0%
90d:
-28.22%
BUY
HIGH Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PLX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: PLX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.06, which is considered slightly high relative to its 30-day fair value range of $1.94 to $2.08. From a valuation perspective, the stock is trading at a premium (Forward PE: 41.2) compared to its historical average (27.1). At these levels, the market is pricing in 15.0% annual earnings growth.
Technical Outlook: Technically, PLX is in a strong downtrend. Immediate support is located at $1.95, while resistance sits at $2.19.
Market Sentiment: PLX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+434.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PLX is in a strong downtrend. Immediate support is located at $1.95, while resistance sits at $2.19.
Market Sentiment: PLX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+434.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.94 -
$2.08
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 434.0% below Wall St target ($11.00)
- BULLISH: Expecting earnings turnaround to 15.0% growth with 233.7% revenue growth
Trading Range Analysis
30-Day Trading Range
$1.94 -
$2.08
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.26
(12.5%)
Support & Resistance Levels
Support Level
$1.95
Resistance Level
$2.19
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
41.20
Wall Street Target
$11.00
(+434.0%)
Revenue Growth (YoY)
233.7%
Earnings Growth (YoY)
-1.0%
Profit Margin
20.1%
Valuation Premium vs History
+15.0% premium
PE vs Historical
41.2 vs 27.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+15.0%
(market-implied from PE analysis)
1-Year Target
$2.37
(+15%)
2-Year Target
$2.72
(+32%)
3-Year Target
$3.13
(+52%)
3-Yr Target (if PE normalizes)
(PE: 41→27)
PE COMPRESSION
$2.06
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 41.2, Growth: -74.4%)
$1.50
(+-27%)
Base:
(SPY PE: 21.8, Growth: -74.4%)
$0.79
(-62%)
Bear:
(PE: 18.5, Growth: -74.4%)
$0.67
(-67%)
📈
Valuation based on Current Earnings
Trailing PE: 11.00 | Current EPS (TTM): $0.19
Bull Case
$1.15
(-44%)
Analyst growth -50.0%, PE expands to 12.1
Base Case
$1.04
(-49%)
Market implied -50.0%, PE stable at 11.0
Bear Case
$1.42
(-31%)
Severe decline -20.0%, PE contracts to 9.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 16, 2026 12:20 AM ET
Data refreshes hourly during market hours. Next update: 1:20 AM
Data refreshes hourly during market hours. Next update: 1:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Dror Bashan
BUY
56000 shares
2025-12-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 50 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$275 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 58 HOLD |
